Search results for: Innovation Policy Prize

Private Provision of Publicly Funded Health Care: The Economics of Ownership

10 September 2018

…reduce waiting times and drive innovation and efficiency improvements. Depending on the viewpoint, private ownership is either a disaster or a salvation for the NHS. A new OHE Briefing, by…

OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer

4 October 2018

…be able to manage a growing number of drugs offering potential cures for a wide range of illnesses. The innovation pipeline includes potential cures for haemophilia, sickle cell disease, and…

Securing Funds for the Proposed NHS Multi-year Funding: The Feasibility of Using a Hypothecated Tax

24 October 2018

…of Health Economics.   Sampson, C., O’Neill, P. and Lorgelly, P. (2018) The Impact of New Medicines in the NHS: 70 Years of Innovation. London: Office of Health Economics.  …

Themes

…value they assign to those outcomes, and how best to incorporate these outcomes and values in decision-making. Policy, Organisation and Incentives in Health Systems Development of effective health system policy…

Around The World in HTAs: Greece – Late but with an Optimistic Future

18 October 2023

…are still a few concerns regarding its structure, the assessment criteria in its clinical parameters, and the prioritization of medicines based on specific parameters such as degree of innovation. There…

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

11 July 2023

…the discussion around dementia policy high in political agendas. Particularly, policies addressing the unmet needs of people living with dementia and a framework supporting informal carers both mentally and financially should be…

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

24 February 2021

…Minister of Health of the Basque Country, and member of OHE Policy Committee); Félix Lobo (President of the Spanish National Health System’s Advisory Committee on Pharmaceutical Provision Financing); former presidents…

Time to Tackle the Challenges around Combination Therapies for Cancer

29 March 2021

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of shorter regimens will take…

ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?

6 June 2022

…the current HTA landscape provides an appropriate reward and therefore incentive for innovation, and how that reward should optimally be determined. He concluded that our current methods offer a good…